Muramyldipeptide augments the actions of lipopolysaccharide in mice by stimulating macrophages to produce pro-IL-1β and by down-regulation of the suppressor of cytokine signaling 1 (SOCS1)

Innate Immunity

Volumn 17, Issue 1, 2011, Pages 3-15

  Shikama, Yosuke ^a   Kuroishi, Toshinobu ^a   Nagai, Yasuhiro ^a   Iwakura, Yoichiro ^b   Shimauchi, Hidetoshi ^a   Takada, Haruhiko ^a   Sugawara, Shunji ^a   Endo, Yasuo ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

inflammatory cytokines; LPS; macrophage; MDP; SOCS1

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MURAMYL PEPTIDE; PROTEIN PRECURSOR; SUPPRESSOR OF CYTOKINE SIGNALING 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; HYPOTHERMIA; MACROPHAGE; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PROTEIN EXPRESSION;

BACTERIA (MICROORGANISMS); MUS;

EID: 79951805135     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425909347508     Document Type: Article

References (57)

1. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006 ; 124: 783-801. (Pubitemid 43261452)
2. Inohara N., Chamaillard M., McDonald C., Nuñez G. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem 2005 ; 74: 355-383. (Pubitemid 40995511)
3. Mitchell JA, Paul-Clark MJ, Clarke GW, McMaster SK, Cartwright N. Critical role of Toll-like receptors and nucleotide oligomerisation domain in the regulation of health and disease. J Endocrinol 2007 ; 193: 323-330. (Pubitemid 47028685)
4. Traub S., von Aulock S., Hartung T., Hermann C. MDP and other muropeptides - direct and synergistic effects on the immune system. J Endotoxin Res 2006 ; 12: 69-85. (Pubitemid 47470157)
5. Girardin SE, Boneca IG, Viala J. et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003 ; 278: 8869-8872. (Pubitemid 36800360)
6. Inohara N., Ogura Y., Fontalba A. et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 2003 ; 278: 5509-5512. (Pubitemid 36800790)
7. Takada H., Galanos C. Enhancement of endotoxin lethality and generation of anaphylactoid reactions by lipopolysaccharides in muramyl-dipeptide-treated mice. Infect Immun 1987 ; 55: 409-413. (Pubitemid 17004120)
8. Car BD, Eng VM, Schnyder B. et al. Interferon ? receptor deficient mice are resistant to endotoxic shock. J Exp Med 1994 ; 179: 1437-1444. (Pubitemid 24129561)
9. Yang S., Takahashi N., Yamashita T. et al. Muramyl dipeptide enhances osteoclast formation induced by lipopolysaccharide, IL-1 α, and TNF-α through nucleotide-binding oligomerization domain 2-mediated signaling in osteoblasts. J Immunol 2005 ; 175: 1956-1964. (Pubitemid 41023103)
10. Park JH, Kim YG, McDonald C. et al. RICK/RIP2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs. J Immunol 2007 ; 178: 2380-2386. (Pubitemid 46233437)
11. Chauhan VS, Sterka Jr DG, Furr SR, Young AB, Marriott I. NOD2 plays an important role in the inflammatory responses of microglia and astrocytes to bacterial CNS pathogens. Glia 2009 ; 57: 414-423.
12. Yoshimura A., Naka T., Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007 ; 7: 454-465. (Pubitemid 46834848)
13. Davey GM, Heath WR, Starr R. SOCS1: a potent and multifaceted regulator of cytokines and cell-mediated inflammation. Tissue Antigens 2006 ; 67: 1-9. (Pubitemid 43381210)
14. Fletcher J., Starr R. The role of suppressors of cytokine signalling in thymopoiesis and T cell activation. Int J Biochem Cell Biol 2005 ; 37: 1774-1786. (Pubitemid 40961663)
15. Ilangumaran S., Ramanathan S., Rottapel R. Regulation of the immune system by SOCS family adaptor proteins. Semin Immunol 2004 ; 16: 351-365. (Pubitemid 39488017)
16. Naka T., Fujimoto M., Tsutsui H., Yoshimura A. Negative regulation of cytokine and TLR signalings by SOCS and others. Adv Immunol 2005 ; 87: 61-122. (Pubitemid 41135899)
17. Kubo M., Hanada T., Yoshimura A. Suppressors of cytokine signaling and immunity. Nat Immunol 2003 ; 4: 1169-1176. (Pubitemid 37540685)
18. Chinen T., Kobayashi T., Ogata H. et al. Suppressor of cytokine signaling-1 regulates inflammatory bowel disease in which both IFN-? and IL-4 are involved. Gastroenterology 2006 ; 130: 373-388. (Pubitemid 43202037)
19. Gingras S., Parganas E., de Pauw A., Ihle JN, Murray PJ Re-examination of the role of suppressor of cytokine signaling 1 (SOCS1) in the regulation of Toll-like receptor signaling. J Biol Chem 2004 ; 279: 54702-54707. (Pubitemid 40053214)
20. Hanada T., Tanaka K., Matsumura Y. et al. Induction of hyper Th1 cell-type immune responses by dendritic cells lacking the suppressor of cytokine signaling-1 gene. J Immunol 2005 ; 174: 4325-4332. (Pubitemid 40396015)
21. Kinjyo I., Hanada T., Inagaki-Ohara K. et al. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity 2002 ; 17: 583-591. (Pubitemid 35351504)
22. Nakagawa R., Naka T., Tsutsui H. et al. SOCS-1 participates in negative regulation of LPS responses. Immunity 2002 ; 17: 677-687. (Pubitemid 35351512)
23. Dinarello CA Interleukin-1 β, interleukin-18, and the interleukin-1 β converting enzyme. Ann NY Acad Sci 1998 ; 856: 1-11.
24. Kanneganti TD, Lamkanfi M., Kim YG et al. Pannexin-1-mediated recognition of bacterial molecules activates the cryopyrin inflammasome independent of Toll-like receptor signaling. Immunity 2007 ; 26: 433-443. (Pubitemid 46603000)
25. Deng X., Yu Z., Funayama H. et al. Mutual augmentation of the induction of the histamine-forming enzyme, histidine decarboxylase, between alendronate and immuno-stimulants (IL-1, TNF, and LPS), and its prevention by clodronate. Toxicol Appl Pharmacol 2006 ; 213: 64-73.
26. Horai R., Asano M., Sudo K. et al. Production of mice deficient in genes for interleukin (IL)-1α, IL-1β, IL-1α/β, and IL-1 receptor antagonist shows that IL-1β is crucial in turpentine-induced fever development and glucocorticoid secretion. J Exp Med 1998 ; 187: 1463-1475. (Pubitemid 28215405)
27. Tagawa Y., Sekikawa K., Iwakura Y. Suppression of concanavalin A-induced hepatitis in IFN-?(-/-) mice, but not in TNF-α(-/-) mice: role for IFN-? in activating apoptosis of hepatocytes. J Immunol 1997 ; 159: 1418-1428. (Pubitemid 127484121)
28. Westphal O., Jann K. Bacterial lipopolysaccharides: extraction with phenol-water and further applications of the procedure. Methods Carbohydr Chem 1965 ; 5: 83-91.
29. Van Rooijen N., Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994 ; 174: 83-93.
30. Yamaguchi K., Yu Z., Kumamoto H. et al. Involvement of Kupffer cells in lipopolysaccharide-induced rapid accumulation of platelets in the liver and the ensuing anaphylaxis-like shock in mice. Biochim Biophys Acta 2006 ; 1762: 269-275. (Pubitemid 43172841)
31. Laemmli UK Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970 ; 227: 680-685.
32. Austyn JM, Gordon S. F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol 1981 ; 11: 805-815. (Pubitemid 12237981)
33. Hirsch S., Austyn JM, Gordon S. Expression of the macrophage-specific antigen F4/80 during differentiation of mouse bone marrow cells in culture. J Exp Med 1981 ; 154: 713-725. (Pubitemid 11060783)
34. Strait RT, Morris SC, Finkelman FD IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc ? RIIb cross-linking. J Clin Invest 2006 ; 116: 833-841. (Pubitemid 43326893)
35. Sha T., Sunamoto M., Kitazaki T., Sato J., Ii M., Iizawa Y. Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model. Eur J Pharmacol 2007 ; 571: 231-239. (Pubitemid 47379694)
36. Günther C., Rollinghoff M., Beuscher HU Formation of intrachain disulfide bonds gives rise to two different forms of the murine IL-1 β precursor. J Immunol 1991 ; 146: 3025-3031.
37. Ferwerda G., Kramer M., de Jong D. et al. Engagement of NOD2 has a dual effect on proIL-1β mRNA transcription and secretion of bioactive IL-1β. Eur J Immunol 2008 ; 38: 184-191.
38. Fritz JH, Girardin SE, Fitting C. et al. Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists. Eur J Immunol 2005 ; 35: 2459-2470. (Pubitemid 41179767)
39. Kim HJ, Yang JS, Woo SS et al. Lipoteichoic acid and muramyl dipeptide synergistically induce maturation of human dendritic cells and concurrent expression of proinflammatory cytokines. J Leukoc Biol 2007 ; 81: 983-989.
40. Yang S., Tamai R., Akashi S. et al. Synergistic effect of muramyldipeptide with lipopolysaccharide or lipoteichoic acid to induce inflammatory cytokines in human monocytic cells in culture. Infect Immun 2001 ; 69: 2045-2053. (Pubitemid 32239668)
41. Landry DW, Oliver JA The pathogenesis of vasodilatory shock. N Engl J Med 2001 ; 345: 588-595.
42. Netea MG, van der Meer JW, van Deuren M., Kullberg BJ Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing?. Trends Immunol 2003 ; 24: 254-258. (Pubitemid 36555964)
43. Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992 ; 101: 1644-1655.
44. Martin GS, Mannino DM, Eaton S., Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003 ; 348: 1546-1554. (Pubitemid 36437931)
45. Ohlsson K., Björk P., Bergenfeldt M., Hageman R., Thompson RC Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990 ; 348: 550-552. (Pubitemid 120015108)
46. Silva AT, Bayston KF, Cohen J. Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-α in experimental Gram-negative shock. J Infect Dis 1990 ; 162: 421-427. (Pubitemid 20239958)
47. Abraham E., Anzueto A., Gutierrez G. et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998 ; 351: 929-933. (Pubitemid 28138465)
48. Fisher Jr CJ, Dhainaut JF, Opal SM et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994 ; 271: 1836-1843. (Pubitemid 24169697)
49. Zeni F., Freeman B., Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997 ; 25: 1095-1100. (Pubitemid 27310241)
50. Mazolewski PJ, Barber A., Williams S., Simoni J., Davis S., Shires GT Attenuating tumor necrosis factor α does not ameliorate other cytokine and peroxidase products during sepsis. Am J Surg 1999 ; 178: 556-559. (Pubitemid 30058310)
51. Dinarello CA Biologic basis for interleukin-1 in disease. Blood 1996 ; 87: 2095-2147. (Pubitemid 26086851)
52. Hazuda DJ, Strickler J., Simon P., Young PR Structure-function mapping of interleukin 1 precursors. Cleavage leads to a conformational change in the mature protein. J Biol Chem 1991 ; 266: 7081-7086. (Pubitemid 21906334)
53. Pan Q., Mathison J., Fearns C. et al. MDP-induced interleukin-1β processing requires Nod2 and CIAS1/NALP3. J Leukoc Biol 2007 ; 82: 177-183. (Pubitemid 47026429)
54. Hsu LC, Ali SR, McGillivray S. et al. A NOD2-NALP1 complex mediates caspase-1-dependent IL-1β secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proc Natl Acad Sci USA 2008 ; 105: 7803-7808. (Pubitemid 351872719)
55. Kobayashi KS, Chamaillard M., Ogura Y. et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005 ; 307: 731-734. (Pubitemid 40194644)
56. Watanabe T., Asano N., Murray PJ et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest 2008 ; 118: 545-559. (Pubitemid 351206545)
57. Martinon F., Agostini L., Meylan E., Tschopp J. Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr Biol 2004 ; 14: 1929-1934. (Pubitemid 39464816)